Research Papers:

Prognostic significance of neutrophil-to-lymphocyte ratio in cervical cancer: A systematic review and meta-analysis of observational studies

Qi-Tao Huang _, Qian-Qian Man, Jia Hu, Yi-lin Yang, Yue-Mei Zhang, Wei Wang, Mei Zhong and Yan-Hong Yu

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:16755-16764. https://doi.org/10.18632/oncotarget.15157

Metrics: PDF 2008 views  |   HTML 4636 views  |   ?  


Qi-Tao Huang1, Qian-Qian Man2, Jia Hu2, Yi-Lin Yang2, Yue-Mei Zhang2, Wei Wang1, Mei Zhong1, Yan-Hong Yu1

1Division of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China

2Southern Medical University, Guangzhou, 510515, China

Correspondence to:

Qi-Tao Huang, email: [email protected]

Mei Zhong, email: [email protected]

Keywords: cervical cancer, inflammatory, neutrophil, lymphocyte, prognosis

Received: September 01, 2016     Accepted: January 06, 2017     Published: February 06, 2017


Background and aims: The prognostic role of neutrophil-to-lymphocyte ratio (NLR) in cervical cancer are controversial. We conducted this meta-analysis to obtain a more accurate assessment of prognostic significance of NLR in cervical cancer.

Results: A total of 9 studies, consisting of 2,804 patients, were selected in this meta-analysis. Our pooled results showed that high pre-treatment NLR level was significantly associated with poorer overall survival (HR: 1.88, 95% CI 1.30–2.73) and shorter progression free survival (HR 1.65, 95% CI 1.18–2.29). Additionally, increased NLR was also significantly correlated with tumor size (OR 2.05, 95% CI 1.14–3.65), advanced FIGO stage (OR 2.12, 95% CI1.28–3.49) and lymph node involvement (OR 2.24, 95% CI 1.65–3.04).

Materials and Methods: We conducted a systematic literature search using the electronic databases PubMed, Web of Science, and Embase up to May 2016.Statistical analysis was performed using Stata 10.0.

Conclusions: Elevated pretreatment NLR could serve as a predicative factor of poor prognosis for cervical cancer patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15157